

One-step labelling of PSMA PET radiotracers with Gallium-68: Utilising the THP chelator

Jennifer D. Young¹, Cinzia Imberti¹, Vincenzo Abbate², Levente K. Meszaros^{1,3}, Michelle T. Ma¹,
Robert C. Hider², Greg E. Mullen^{1, 3}, Philip J. Blower¹

1. King's College London, Division of Imaging Sciences and Biomedical Engineering, London, United Kingdom

2. King's College London, Institute of Pharmaceutical Science, London, United Kingdom

3. Theragnostics Ltd


Ga-68: the new Tc-99m?

^{68}Ga : short half life (68 min) positron emitter
versatile, generator produced....what's not to like?




- Tc-99m generator and *kits* revolutionised nuclear medicine in 1970s - available in all major hospitals
- In most cases, all we need is the generator, syringe, shield and single kit vial
- Can we do this with ^{68}Ga ?
 - We have ^{68}Ga generator: E&Z generator: marketing authorisation in 2014, others on track
 - We have chelators, lots of them...
- In theory YES...
- ...In practice NO
- Current Ga-68 chelators need one or more of: heat (90°C), time (30 min), acid, purification step, automated cartridge-based system
- A one step “shake and ^{no}bake” kit - syringe and vial - would make Ga-68 PET accessible to more centres – wide patient impact

To paraphrase Alan Jay Lerner:

“Why can't gallium be more like technetium?”




What is a “kit”?


- Cartridge for an automated synthesis module to automate a multi-step series of reactions, perhaps including purification? 
- Set of vials and reagents for multistep manual labelling (e.g. including pH adjustment, heat, purification...)? 
- A single vial into which generator eluate can be injected to produce the final product ready for patient administration in 1 – 2 min at room temperature?
 - Then have a cup of tea
 - Like most Tc-99m labelling since 1970s

Tris(hydroxypyridinone) ligands


- To achieve rapid room temperature labelling we need a chelator with low barriers to chelation
- But with short half life (68 min) we can sacrifice some in vivo kinetic stability
- Strategy:
 - Abandon macrocyclic chelators
 - Learn from iron chelators (Fe^{3+} and Ga^{3+} have same charge, very similar ionic radius)



Deferiprone




THP-Ac²




THP-mal²

Comparison with accepted chelators: two methods

1. Measure labelling efficiency at progressively lower ligand concentration (fixed time, temp, pH)
2. Label 1:1 mixture of two chelators, analyse by HPLC (fixed time, temp, pH)
 - the "FIGHT!" method



Method 1: reduce concentration




Competition studies

First measure radio-HPLC of ^{68}Ga -complex - characteristic retention time


Then: Chelators mixed in a 1:1 ratio and labelled with ^{68}Ga

...example HBED vs.DFO


HBED, pH 4




DFO, pH 4



HBED vs. DFO, pH 4



HBED vs. DFO, pH 7




Retention time (min)

Competition results, room temp, pH 7


	DOTA	NOTA	NOTP	HBED	TRAP	THP-Ac	DFO
DOTA				98.8% HBED		100% THP-Ac	100% DFO
NOTA				41.4% HBED		99% THP-Ac	32.8% DFO
NOTP				0% HBED		92% THP-Ac	25.6% DFO
HBED	1.2% DOTA	58.6% NOTA	100% NOTP		61.9% TRAP	100% THP-Ac	18.4% DFO
TRAP				38.1% HBED		100% THP-Ac	25% DFO
THP-Ac	0% DOTA	1% NOTA	8% NOTP	0% HBED	0% TRAP		0% DFO
DFO	0% DOTA	67.2% NOTA	74.4% NOTP	81.6% HBED	75% TRAP	100% THP-Ac	

In every 2-way fight, THP-Ac wins by at least an order of magnitude
Similar results at pH 4


New variants of THP




THP-Ac




THP-mal




H₃THP²



THP-NH₂



THP-NCS




THP-PhNCS


Can this advantage be turned into simple kits?

THP-PSMA Tracer Design


HBED-CC-PSMA




Specific target for prostate cancer



THP-PSMA



Specific target for prostate cancer



Aim:

Deliver a tracer that specifically targets prostate cancer



and

can be labelled quickly and easily


to

widen the adoption of PSMA imaging

^{68}Ga -HBED-CC-PSMA: game-changer in prostate cancer...



Room temperature labelling




95°C labelling

...**BUT** Multiple step synthesis
35 minutes
Requires a synthesis
unit/cartridge
Isomers formed


THP-PSMA:

Development of radiolabelling process



HPLC


Agilent Eclipse XDB C₁₈
5 micron 4.6 x 150 mm
Isocratic mobile phase:
87.5% H₂O, 12.5% ACN,
0.075% TFA, 0.05% TEA, 1 mL/min



iTLC


Varian SG I0001 strips (10cm length)
1M ammonium acetate in
water/methanol (1:1)

iTLC trace



R_f = 0; un chelated ⁶⁸Ga
R_f = 0.8-1; ⁶⁸Ga-THP-PSMA

Radiochemical Purity



THP-PSMA: Single vial kit labelling

E & Z generator



5mL, 0.1M HCL

5mL eluate
122-202 MBq

Freeze dried kit


THP-PSMA
(40µg 26nmol)
sodium bicarbonate
(44mg)
sodium phosphate
buffer (157.5mg)

pH 6-7

N=3

iTLC results over time

5 mL kits



IRE generator



1.1mL, 0.1M HCL

1mL eluate
600-660 MBq
+ 4mL 0.1M HCL


Freeze dried kit

THP-PSMA
(40µg 26nmol)
sodium bicarbonate
(44mg)
sodium phosphate
buffer (157.5mg)

pH 6-7

N=3

Example HPLC result: 10 min post reconstitution



THP-PSMA: Conclusion

Result

Aim: To label a PSMA radiotracer with ^{68}Ga , in a simple and rapid procedure, suitable for translation into a GMP radiopharmaceutical kit



Single vial, single step synthesis
2-5 minutes, single isomer

PSMA: Phase 2 multicentre trial ongoing

*Thp is a **platform** for new generation of kit-based Ga-68 imaging agents including proteins (e.g. scFv antibodies)*

Note: ^{68}Ga generators utilised must have ^{68}Ge breakthrough low enough for direct human use $< 0.001\%$.
Eckert and Ziegler Radiopharma GmbH (E&Z) and Galli EO IRE ELiT (IRE) generators meet this criteria.

Thank You

People:

Jennifer Young, Michael S. Hofman, Peter Eu, Amir Iravani, Declan Murphy, Catherine Mitchell, Rodney J. Hicks, Cinzia Imberti, Vincenzo Abbate, Michelle Ma, Levente Meszaros, Robert Hider, Jeevan Virk, Victoria Gibson, Maggie Cooper, Greg Mullen, Philip Blower.

Funding:



THERAGNOSTICS

Disclosure

Authors include employees of Theragnostics and inventors named on patent owned by King's

Institutions:

